| Nivolumab in previously untreated melanoma without BRAF mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015 | 6008 | 2015 |
| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 2189 | 2017 |
| Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ... CA: a cancer journal for clinicians 67 (6), 472-492, 2017 | 2110 | 2017 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 1973 | 2014 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1533 | 2015 |
| Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ... New England Journal of Medicine 381 (7), 626-636, 2019 | 1149 | 2019 |
| Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ... The Lancet Oncology 19 (5), 603-615, 2018 | 976 | 2018 |
| Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma HA Tawbi, D Schadendorf, EJ Lipson, PA Ascierto, L Matamala, ... New England Journal of Medicine 386 (1), 24-34, 2022 | 968 | 2022 |
| The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma EM Van Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, ... Cancer discovery 4 (1), 94-109, 2014 | 960 | 2014 |
| Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma A Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ... Journal of clinical oncology 31 (5), 616, 2013 | 885 | 2013 |
| Prognostic significance of autoimmunity during treatment of melanoma with interferon H Gogas, J Ioannovich, U Dafni, C Stavropoulou-Giokas, K Frangia, ... New England Journal of Medicine 354 (7), 709-718, 2006 | 762 | 2006 |
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ... Annals of Oncology 28 (7), 1631-1639, 2017 | 715 | 2017 |
| Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma D Liu, B Schilling, D Liu, A Sucker, E Livingstone, L Jerby-Arnon, ... Nature medicine 25 (12), 1916-1927, 2019 | 624 | 2019 |
| Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label … R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ... The Lancet Oncology 19 (10), 1315-1327, 2018 | 579 | 2018 |
| Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the … R Gutzmer, D Stroyakovskiy, H Gogas, C Robert, K Lewis, S Protsenko, ... The Lancet 395 (10240), 1835-1844, 2020 | 570 | 2020 |
| Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled … PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ... The Lancet Oncology 21 (11), 1465-1477, 2020 | 435 | 2020 |
| Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study JL Mansi, H Gogas, JM Biss, JC Gazet, U Berger, RC Coombes The Lancet 354 (9174), 197-202, 1999 | 392 | 1999 |
| Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial PA Ascierto, GV Long, C Robert, B Brady, C Dutriaux, AM Di Giacomo, ... JAMA oncology 5 (2), 187-194, 2019 | 345 | 2019 |
| Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ... European journal of cancer 51 (18), 2792-2799, 2015 | 335 | 2015 |
| Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study J Larkin, M Del Vecchio, PA Ascierto, I Krajsova, J Schachter, B Neyns, ... The Lancet Oncology 15 (4), 436-444, 2014 | 316 | 2014 |
Urania DafniProfessor of Biostatistics, National and Kapodistrian University of Athens, GreeceΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα nurs.uoa.gr
